This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health Announces New Evidence Further Demonstrating Clinical Utility And Cost-Effectiveness Of Oncotype DX In Colon Cancer

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX ® Colon Cancer test  at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score ® (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients.  Presentations also include positive findings from a second health economics analysis suggesting that use of the test may result in a significant reduction in direct medical costs and improve patient well-being.

Additionally, the company announced that the Journal of Clinical Oncology (JCO) has accepted for publication results from its second large clinical validation study of stage II colon cancer patients enrolled in CALGB 9581 confirming that the Oncotype DX test improves the ability to differentiate higher from lower recurrence risk beyond conventional factors.

"These new data reinforce the value of an individualized recurrence risk assessment score that enables physicians to identify those at high risk of recurrence who can experience a greater potential benefit from chemotherapy, as well as patients with a low risk of recurrence who can be spared unnecessary treatment," said Steven Shak, M.D., chief medical officer and executive vice president for research and development at Genomic Health.  "Oncotype DX represents an important advance in bringing personalized medicine into the modern paradigm for cancer care.  With a growing body of evidence, and a second publication in JCO, we now have expanded support for broader reimbursement and increased patient access to our colon cancer test."

Oncotype DX Colon Cancer Test Changes 45 Percent of Treatment Decisions

"Current clinical practice reveals a high level of variability and subjectivity in the treatment of stage II colon cancer patients," said Steven Alberts, M.D., medical director for the Clinical Research Office in the Mayo Clinic Cancer Center, Rochester, Minn.  "The Oncotype DX Colon Cancer test changes the paradigm for predicting individual recurrence risk for stage II colon cancer patients by providing quantitative information which has not been available with conventional measures."

  • Conducted in collaboration with the Mayo Clinic Cancer Research Consortium, a prospectively designed study analyzed treatment decisions for 141 stage II, T3 MMR-proficient colon cancer patients across 17 sites demonstrating that the use of the Oncotype DX Colon Cancer test changed treatment decisions 45 percent of the time and led to an overall reduction in chemotherapy use. 

For patients whose treatment recommendations changed, treatment intensity decreased for more than 33 percent of patients (from chemotherapy to observation or from oxaliplatin-containing to non-oxaliplatin containing regimens) and increased for more than 11 percent of patients (from observation to any chemotherapy or from non-oxaliplatin containing to oxaliplatin-containing treatment). 

Abstract #453: "Prospective evaluation of a 12-gene assay on treatment recommendations in stage II colon cancer patients" will be presented on Saturday, January 26, from 7:00–7:55 a.m. Pacific Time at Moscone West, San Francisco, Calif.

Second Health Economics Study Reconfirms Test's Cost Effectiveness

  • An analysis of 141 patients from 17 sites in the Mayo Clinic Cancer Research Consortium demonstrated the value of using the Oncotype DX test to identify stage II colon cancer patients with low risk of recurrence. After receiving the Recurrence Score results, physician recommendations for adjuvant chemotherapy in patients with low risk of recurrence decreased by 22 percent, which resulted in direct medical care costs savings of $4,200 per patient.

This is the first health economic study of the Oncotype DX Colon Cancer test conducted in clinical practice.  A separate modeling study showing that the use of the Oncotype DX test in stage II colon cancer patients may lead to health care cost savings while improving clinical outcomes was recently published in the December 2012 issue of Value of Health.

Abstract #391: "Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer" will be presented on Saturday, January 26, from 7:00–7:55 a.m. Pacific Time at Moscone West, San Francisco, Calif.

Additionally, the company will present a poster titled: "Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers" (Abstract #349) on Saturday, January 26, from 7:00 – 7:55 a.m. Pacific Time at Moscone West, San Francisco, Calif.

Four leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Gastroenterological Association Institute, the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Surgical Oncology (SSO). 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,911.65 -158.75 -0.88%
S&P 500 2,091.79 -22.70 -1.07%
NASDAQ 4,940.3570 -76.5720 -1.53%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs